DiGeorge Syndrome Drug Market size is set to register remarkable growth rate during the forecast period i.e., between 2024-2036.
The market growth is driven by the growing patient pool of the disease and the need for treatment for the wide range of symptoms caused by this genetic disorder. The symptoms of this disorder include congenital heart disease, cleft palate, learning and development delay, and mental disorders including autism spectrum disorder (ASD), anxiety disorder, and psychotic disorders, such as, schizophrenia among others. These symptoms may vary from person to person, which induces the need for a different and specific treatment approach for every individual. This, in turn, is estimated to boost the market growth by the end of 2029. Moreover, the cause of deletion of chromosome 22 is still unknown, creating vast scope for research activities in this direction, which is estimated to generate immense opportunity for the market growth throughout the forecast period.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
Regional Scope |
|
The global DiGeorge syndrome drug market is segmented based on route of administration into oral and injectable, out of which, the oral administration segment is anticipated to garner major share during the forecast period in the market considering the ease and convenience of receiving the treatment. Based on end-user, the market is segmented into hospitals, homecare, speciality clinics and others, out of which speciality clinics are anticipated to hold a significant market share by the end of 2029 as these clinics are mostly preferred by patients owing to the availability of focused and specified treatment for the DiGeorge syndrome.
However, the treatment can be very expensive and long-stretched, causing financial and mental stress to the patients and their family. This can act as a restraint for the growth of the market. Additionally, with the expiry of patents of drugs from many companies, the chance of generic drugs being introduced in the market is high, which is further estimated, to hamper market growth over the forecast period.
Our in-depth analysis of the global market includes the following segments
|
By Route of administration |
|
|
By Therapy Type |
|
|
By End-Users |
|
North America Market Statistics
On the basis of regional analysis, the global DiGeorge syndrome drug market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
North America industry is estimated to hold largest revenue share by 2036, on the back of rising prevalence of the disorder. DiGeorge syndrome occurs in 1 in every 3000 to 6000 births in the U.S. and its proximity is equal between males and females. Additionally, the market is projected to witness significant growth owing to the growing medical advancements combined with efficient healthcare sector in the region. According to the World Health Organization (WHO), as of 2018, 16.416 % of the GDP was spent on the healthcare sector in North America. Moreover, increasing investments by the government on research and development activities for the development of newer treatment methods and more effective drugs are additional factors estimated to contribute towards the market growth in the forecast period.
APAC Market Analysis
The market in the Asia Pacific is anticipated to witness notable growth accounting to the increasing population and prevalence of DiGeorge syndrome in the region. Gradual, yet constant development in the public healthcare system in the APAC region also tends to positively affect the market growth.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?